Skip to main content

Advertisement

Table 1 Patient characteristics

From: Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

Age (Years) Median [range] 53 (24–79)
<35 (%) 30 (4 %)
≥70 (%) 43 (6 %)
Type of surgery Lumpectomy 552 (73 %)
Complete mastectomy 205 (27 %)
Axillary management Lymph node dissection 395 (52 %)
Sentinel lymph node biopsy 362 (48 %)
Histological type Invasive ductal carcinoma 599 (79 %)
Invasive lobular carcinoma 66 (9 %)
Other invasive carcinoma 92 (12 %)
Pathological tumor size (pT) pT1a-b 63 (8 %)
pT1c 329 (44 %)
pT2 320 (43 %)
pT3-T4 36 (5 %)
SBR grade 1 132 (18 %)
2 331 (44 %)
3 285 (38 %)
NA 9
Peritumoral vascular invasion (PVI) No 558 (76 %)
Yes 174 (24 %)
NA 25
Hormone receptors
 ER Negative 229 (31 %)
Positive 506 (69 %)
NA 32
 PR Negative 287 (39 %)
positive 441 (61 %)
NA 29
 ER or PR Negative 208 (28 %)
Positive 527 (72 %)
NA 22
HER2 status Positive 96 (16 %)
Negative 508 (84 %)
NA 153
IHC subtypes Triple-negative 127 (21 %)
Luminal A 290 (49 %)
Luminal B/HER2-negative 82 (14 %)
Luminal B/HER2-positve 58 (10 %)
HER2 37 (6 %)
NA 163
Adjuvant chemotherapy FEC 100 716 (94 %)
FEC 50/75 41 (6 %)
Adjuvant hormone therapy Yes 532 (70 %)
No 224 (30 %)
NA 1
Adjuvant radiation therapy Yes 681 (90 %)
No 76 (10 %)
Adjuvant trastuzumab (HER2-positive) Yes 40 (41 %)
No 56 (59 %)